Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer gets license to Sangamo's ZFN technology

Executive Summary

In a royalty-free agreement, Sangamo BioSciences (developing zinc finger DNA-binding proteins or ZFPs) has licensed Pfizer global nonexclusive rights to use certain ZFP nuclease (ZFN) reagents to eliminate the glutamine synthetase (GS) gene in Chinese hamster ovary (CHO) cell lines. Pfizer also gets rights to use the ZFN-modified cells for clinical and commercial production of protein therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies